Dynamic Observation in Children and Adolescents Following Management of Differentiated Thyroid Cancer

Differentiated thyroid cancer (DTC) is one of the most common malignancies within the endocrine system, with a progressively increasing incidence over recent decades. In the structure of DTC, occurrence in the pediatric age group is relatively rare and is associated with excellent prognoses in terms of disease-specific survival. However, the prevalence of advanced disease in children and the frequency of recurrences present interdisciplinary teams with questions regarding the optimal management approach for such patients, focusing not on achieving disease eradication but preserving and maintaining quality of life. Notably, the presence of oncological pathology, coupled with fluctuations in thyroid hormone levels due to therapeutic interventions, underscores the importance of maintaining psychological and physiological well-being that are affected by the increased frequency of anxiety and depressive symptoms in children and their parents, as well as cognitive and physical functioning. These symptoms may exacerbate against the backdrop of hypothyroidism and directly correlate with TSH levels. To maintain quality of life during the period of dynamic observation and risk group re-stratification, we proposed a method of reduced thyroid hormone doses as an alternative to discontinuing thyroid hormones to assess stimulated thyroglobulin when reaching a threshold TSH level >30 mIU/L. The method was implemented in 2 pediatric patients, showing positive outcomes in terms of absence of hypothyroidism-related complaints, preservation of free thyroid hormone fractions, achievement of adequate target TSH levels, and informative tumor marker indicators. The results of our study underscore the importance of an individualized approach to the management of children with DTC and demonstrate the potential effectiveness of the reduced dose method in maintaining the quality of life of these patients. Further research and clinical observations are necessary for a deeper understanding of the applicability of this method and its impact on longterm outcomes.

1. Prasad PK, Mahajan P, Hawkins DS, et al. Management of pediatric differentiated thyroid cancer: An overview for the pediatric oncologist. Pediatric Blood & Cancer. 2020. e28141. doi: https://doi.org/10.1002/pbc.28141

2. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’) / pod red. A.D. Kaprina, V.V. Starinskogo, A.O. SHahzadovoj. Moskva: MNIOI im. P.A. Gercena − filial FGBU «NMIC radiologii» Minzdrava Rossii, 2022 (In Russ)]

3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2016. National Cancer Institute; Bethesda, MD, USA: 2019

4. Christison-Lagay ER, Baertschiger RM, Dinauer C, et al. Pediatric differentiated thyroid carcinoma: An update from the APSA Cancer Committee. J Pediatr Surg. 2020;55(11):2273-2283. doi: https://doi.org/10.1016/j.jpedsurg.2020.05.003

5. Paulson VA, Rudzinski ER, Hawkins DS. Thyroid Cancer in the Pediatric Population. Genes (Basel). 2019;10(9):723. doi: https://doi.org/10.3390/genes10090723

6. Ajani MA, Omenai SA, Nwadiokwu JI, Salami AA. Histopathological profile of childhood thyroid carcinoma in Ibadan, Southwestern Nigeria. Malawi Med J. 2020;32(4):213-217. doi: https://doi.org/10.4314/mmj.v32i4.6

7. Francis GL, Waguespack SG, Bauer AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25:716–759

8. Galuppini F, Vianello F, Censi S, et al. Differentiated Thyroid Carcinoma in Pediatric Age: Genetic and Clinical Scenario. Front Endocrinol (Lausanne). 2019;10:552. doi: https://doi.org/10.3389/fendo.2019.00552

9. Tian T, Huang S, Dai H, et al. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid Cancer in Children, Adolescents, and Young Adults. J Clin Endocrinol Metab. 2023;108(2):306-314. doi: https://doi.org/10.1210/clinem/dgac600

10. Waguespack S, Wells S, Ross J, Bleyer A. Thyroid Cancer. National Cancer Institute, Bethesda, MD. 2006

11. Christine EC, Ari JW. Pediatric thyroid cancer: Recent developments. Best Practice & Research Clinical Endocrinology & Metabolism. 2023;37(1):101715. doi: https://doi.org/10.1016/j.beem.2022.101715

12. Abelleira E, Jerkovich F. Dynamic risk assessment in patients with differentiated thyroid cancer. Rev Endocr Metab Disord. 2024;25:79-93. doi: dhttps://doi.org/10.1007/s11154-023-09857-7

13. Differentiated thyroid cancer. Clinical recommendations. Journal of Modern Oncology. 2020;22(4):30–44. (In Russ)]. doi: https://doi.org/10.26442/18151434.2020.4.200507

14. Bryan RH, Erik KA, Keith CB, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016:1-133. doi: https://doi.org/10.1089/thy.2015.0020

15. Gamper EM, Wintner LM, Rodrigues M, et al. Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme. Eur J Nucl Med Mol Imaging. 2015;42:1179–1188. doi: https://doi.org/10.1007/s00259-015-3022-9

16. Kirnap NG, İyidir ÖT, Bozkuş Y, et al. The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma. Turkish Journal of Medical Sciences. 2020;50(4):Article 30. doi: https://doi.org/10.3906/sag-1902-176

17. Helvacı BC, Yalçın MM, Yalcın ŞNG, Arslan E, Altinova AE, Törüner FB. Differentiated thyroid cancer: effect on quality of life, depression, and anxiety. Hormones (Athens). 2023;22(3):367-374. doi: https://doi.org/10.1007/s42000-023-00449-3

18. Melanie G, Jacqueline C. Thyroid Cancer–Specific Quality of Life and Health-Related Quality of Life in Young Adult Thyroid Cancer Survivors. Thyroid. 2016:923-932. doi: shttp://doi.org/10.1089/thy.2015.0589

19. Mongelli MN, Giri S, Peipert BJ, et al. Financial burden and quality of life among thyroid cancer survivors. Surgery. 2020;167(3):631-637. doi: https://doi.org/10.1016/j.surg.2019.11.014

20. Zeltzer LK, Lu Q, Leisenring W, et al. Psychosocial outcomes and health-related quality of life in adult childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008;17:435–446. doi: https://doi.org/10.1158/1055-9965.EPI-07-2541

21. Dionisi-Vici M, Fantoni M, Botto R, et al. Distress, anxiety, depression and unmet needs in thyroid cancer survivors: a longitudinal study. Endocrine. 2021;74:603–610. doi: https://doi.org/10.1007/s12020-021-02786-y

22. Tagay S, Herpertz S, Langkafel M, et al. Health-related Quality of Life, Depression and Anxiety in Thyroid Cancer Patients. Quality of Life Research. 2006;15(4):695–703. doi: https://doi.org/10.1007/s11136-005-3689-7

23. Lee JI, Kim SH, Tan AH, et al. Decreased health-related quality of life in disease-free survivors of differentiated thyroid cancer in Korea. Health Qual Life Outcomes. 2010;8:101. doi: https://doi.org/10.1186/1477-7525-8-101

24. Nies M, Mariëlle MSK, Huizinga GA, et al. Long-Term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2017;102(4):1218–1226. doi: https://doi.org/10.1210/jc.2016-2246

25. Perez MN, Halada S, Isaza A, et al. Health-Related Quality of Life at Diagnosis for Pediatric Thyroid Cancer Patients. J Clin Endocrinol Metab. 2023;108(5):e169-e177. doi: https://doi.org/10.1210/clinem/dgac648

26. Giusti M, Gay S, Conte L, et al. Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the ThyroidSpecific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study. European Thyroid Journal. 2020;9(5):247-255. doi: https://doi.org/10.1159/000501201

27. Oren A, Benoit MA, Murphy A, et al. Quality of Life and Anxiety in Adolescents with Differentiated Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2012;97(10):E1933–E1937. doi: https://doi.org/10.1210/jc.2012-1823

28. Chaker L, Razvi S, Bensenor IM, et al. Hypothyroidism. Nature Reviews Disease Primers. 2022;8(1). doi: https://doi.org/10.1038/s41572-022-00357-7

29. An YS, Lee J, Kim HK, et al. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients. Sci Rep. 2023;13(1):206. doi: https://doi.org/10.1038/s41598-023-27455-0

30. Han YH, Lim ST, Yun KN, et al. Comparison of the Influence on the Liver Function Between Thyroid Hormone Withdrawal and rh-TSH Before High-Dose Radioiodine Therapy in Patients with Well-Differentiated Thyroid Cancer. Nucl Med Mol Imaging. 2012;46(2):89-94. doi: https://doi.org/10.1007/s13139-012-0132-1

31. Göbel A, Heldmann M, Göttlich M, et al. Partial withdrawal of levothyroxine treated disease leads to brain activations and effects on performance in a working memory task: A pilot study. J Neuroendocrinol. 2019;31(4):e12707. doi: https://doi.org/10.1111/jne.12707

32. Deng H. Cardiovascular Risk Factors in Children and Adolescents with Subclinical Hypothyroidism: A Meta-analysis and Systematic Review. 2021. PREPRINT (Version 1) available at Research Square. doi: https://doi.org/10.21203/rs.3.rs-1023396/v1

33. Sayari S, Molaei Z, Torabi Z. The relationship between subclinical hypothyroidism and serum levels of uric acid and creatinine in children aged 2-14 years. Ann Pediatr Endocrinol Metab. 2018;23(1):38-42. doi: https://doi.org/10.6065/apem.2018.23.1.38

34. Patel R, Dave C, Mehta S, et al. Metabolic Impact of Subclinical Hypothyroidism in Obese Children and Adolescents. Indian J Pediatr. 2021;88:437–440. doi: https://doi.org/10.1007/s12098-020-03463-0

35. Alexander K, Lee SC, Georgiades S, Constantinou C. The «not so good» thyroid cancer: a scoping review on risk factors associated with anxiety, depression and quality of life. J Med Life. 2023;16(3):348-371. doi: https://doi.org/10.25122/jml-2022-0204

36. Habib A, Habib A. No association between subclinical hypothyroidism and dyslipidemia in children and adolescents. BMC Pediatr. 2020;20(1):436. doi: https://doi.org/10.1186/s12887-020-02318-z

37. Pérez-Lobato R, Ramos R, Arrebola JP, et al. Thyroid status and its association with cognitive functioning in healthy boys at 10 years of age. European Journal of Endocrinology. 2015;172:129–139. doi: https://doi.org/10.1530/EJE-14-0093

38. Ergür AT, Taner Y, Ata E, et al. Neurocognitive functions in children and adolescents with subclinical hypothyroidism. Journal of Clinical Research in Pediatric Endocrinology. 2012;4:21–24. doi: https://doi.org/10.4274/Jcrpe.497

39. Aijaz NJ, Flaherty EM, Preston T, et al. Thyroid-related neurological disorders and complications in children. Pediatr Neurol. 2015;52(4):373-382

40. Ingerski LM, Modi AC, Hood KK, et al. Health-related quality of life across pediatric chronic conditions. J Pediatr. 2010;156(4):639-644. doi: https://doi.org/10.1016/j.jpeds.2009.11.008

41. Mostoufi-Moab S, Barakat LP, Bauer AJ. Quality of Life in Adolescent Patients with Differentiated Thyroid Cancer: Moving beyond Survival. The Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3453–3456. doi: https://doi.org/10.1210/jc.2012-3070

42. Rosário PW, Vasconcelos FP, Cardoso LD, et al. Managing thyroid cancer without thyroxine withdrawal. Arquivos Brasileiros de Endocrinologia & Metabologia. 2006;50(1):91–96. doi: https://doi.org/10.1590/s0004-27302006000100013

43. Albano D, Bertagna F, Panarotto MB, Giubbini R. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. Pediatr Blood Cancer. 2017;64(11):10.1002/pbc.26595. doi: https://doi.org/10.1002/pbc.26595